Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
”New evidence on “aspirin failure” after ischemic stroke
Patients who suffer an ischemic stroke while already taking aspirin represent a high-risk and frustrating clinical group.
The common reflex is to switch antithrombotic therapy—but does it actually help?
A new systematic review and network meta-analysis of 9 randomized trials (5,459 patients, median follow-up ~19 months) found:
- Switching to another antithrombotic (DOAC, DAPT, or warfarin) did not significantly reduce recurrent ischemic stroke compared with continuing aspirin
- No significant benefit was seen for the composite outcome of stroke, MI, or death
- DOACs (dabigatran, apixaban) and aspirin plus low-dose rivaroxaban ranked highest in network analyses—but none were superior to aspirin
Bottom line: After an ischemic stroke on aspirin, simply switching antithrombotic therapy may not meaningfully improve outcomes.
This highlights a major unmet need—and the importance of trials designed specifically for this growing population.
Read the full article here.”
Article: Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis
Authors: Aaron Rothstein, Ossama Khazaal, Steven Messe, Yulun Liu, Sean Hennessy, Yong Chen, Ale Algra, Shinichiro Uchiyama, Sven Poli, Tobias Geisler, Lina Maria Serna Higuita, Kanjana Perera, Amanda Taylor, Scott E. Kasner
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 13, 2026, 04:18Stephen Cornelissen: You Might Be Eligible to Donate Blood – Here’s Why It’s Worth Checking
-
Apr 13, 2026, 04:12Angie Read: A Powerful Conversation on Survival, Recovery, and Purpose on Stroke Sisters’ Latest Episode
-
Apr 13, 2026, 04:04Ramy Abdelnaby: Telestroke Rounds Show Superior Guideline Adherence in Subacute Care
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow